Trustmark National Bank Trust Department’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.01M | Sell |
25,560
-828
| -3% | -$124K | 0.24% | 78 |
|
|
2026
Q1 | $4.03M | Sell |
26,388
-448
| -2% | -$68.7K | 0.26% | 75 |
|
|
2025
Q4 | $3.7M | Sell |
26,836
-52
| -0.2% | -$6.81K | 0.23% | 76 |
|
|
2025
Q3 | $3.45M | Sell |
26,888
-318
| -1% | -$38.8K | 0.22% | 85 |
|
|
2025
Q2 | $3.29M | Sell |
27,206
-131
| -0.5% | -$14.8K | 0.23% | 88 |
|
|
2025
Q1 | $3.05M | Sell |
27,337
-27,867
| -50% | -$2.97M | 0.23% | 88 |
|
|
2024
Q4 | $5.37M | Sell |
55,204
-9,813
| -15% | -$1.05M | 0.4% | 58 |
|
|
2024
Q3 | $7.48M | Sell |
65,017
-1,615
| -2% | -$183K | 0.57% | 39 |
|
|
2024
Q2 | $7.09M | Buy |
66,632
+663
| +1% | +$66.6K | 0.57% | 37 |
|
|
2024
Q1 | $6.38M | Sell |
65,969
-2,025
| -3% | -$208K | 0.52% | 43 |
|
|
2023
Q4 | $6.87M | Sell |
67,994
-1,292
| -2% | -$125K | 0.63% | 37 |
|
|
2023
Q3 | $7.06M | Buy |
69,286
+40
| +0.1% | +$4.06K | 0.7% | 30 |
|
|
2023
Q2 | $6.99M | Buy |
69,246
+4,987
| +8% | +$499K | 0.65% | 33 |
|
|
2023
Q1 | $5.91M | Buy |
+64,259
| New | +$5.61M | 0.54% | 44 |
|
|
2021
Q3 | – | Sell |
-3,449
| Closed | -$314K | – | 254 |
|
|
2021
Q2 | $314K | Sell |
3,449
-1,885
| -35% | -$168K | 0.02% | 213 |
|
|
2021
Q1 | $456K | Sell |
5,334
-260
| -5% | -$23.3K | 0.04% | 187 |
|
|
2020
Q4 | $528K | Hold |
5,594
| – | – | 0.05% | 171 |
|
|
2020
Q3 | $486K | Buy |
+5,594
| New | +$485K | 0.05% | 173 |
|
|
2019
Q3 | – | Sell |
-1,979
| Closed | -$180K | – | 439 |
|
|
2019
Q2 | $180K | Buy |
+1,979
| New | +$167K | 0.02% | 245 |
|
|
2017
Q2 | – | Sell |
-4,627
| Closed | -$308K | – | 269 |
|
|
2017
Q1 | $308K | Buy |
4,627
+432
| +10% | +$28.8K | 0.04% | 212 |
|
|
2016
Q4 | $274K | Buy |
+4,195
| New | +$272K | 0.04% | 214 |
|
|
2015
Q3 | – | Sell |
-2,748
| Closed | -$242K | – | 358 |
|
|
2015
Q2 | $242K | Sell |
2,748
-136
| -5% | -$12.5K | 0.03% | 306 |
|
|
2015
Q1 | $255K | Buy |
+2,884
| New | +$256K | 0.03% | 304 |
|
|
2014
Q4 | – | Sell |
-4,234
| Closed | -$357K | – | 325 |
|
|
2014
Q3 | $357K | Sell |
4,234
-270
| -6% | -$21.8K | 0.05% | 262 |
|
|
2014
Q2 | $366K | Sell |
4,504
-2,344
| -34% | -$184K | 0.04% | 269 |
|
|
2014
Q1 | $522K | Sell |
6,848
-203
| -3% | -$14.8K | 0.06% | 230 |
|
|
2013
Q4 | $507K | Sell |
7,051
-19
| -0.3% | -$1.32K | 0.06% | 227 |
|
|
2013
Q3 | $486K | Hold |
7,070
| – | – | 0.06% | 214 |
|
|
2013
Q2 | $447K | Buy |
+7,070
| New | +$460K | 0.06% | 216 |
|
Other funds holding NVS
Trustmark National Bank Trust Department's NVS Position: Q2 2026 in Review
Trustmark National Bank Trust Department reduced its Novartis (NVS) stake by 3.1% in Q2 2026, selling an estimated $124K and leaving 25,560 shares worth $4.01M. The position accounts for 0.24% of the portfolio, ranked #78.
Trustmark National Bank Trust Department first reported a position in NVS in Q2 2013 and has held it in 29 quarters since. The position peaked at $7.48M in Q3 2024. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Trustmark National Bank Trust Department held 25,560 shares of Novartis worth $4.01M as of Q2 2026.
- Trustmark National Bank Trust Department sold 828 Novartis shares in Q2 2026, an estimated $124K.
- Novartis made up 0.24% of Trustmark National Bank Trust Department's portfolio in Q2 2026, its #78 holding.
- Trustmark National Bank Trust Department first reported a position in Novartis in Q2 2013 and has held it in 29 quarters since.
- Trustmark National Bank Trust Department's Novartis position peaked at $7.48M in Q3 2024.
- 1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Trustmark National Bank Trust Department's 13F filing for Q2 2026, filed 12 Aug 2026.